TL;DR
This study tracked the blood counts of patients with polycythemia vera (PV) and essential thrombocythemia (ET) in the UK over five years, revealing that achieving complete remission of key blood markers is challenging in real-world clinical practice. Importantly, the research found no statistically significant link between achieving these remission targets early on and an increased risk of cardiovascular events.
What Problem Does This Paper Address?
Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms (MPNs) characterized by the overproduction of blood cells. While guidelines exist for managing these conditions, there's limited real-world data on how effectively patients achieve target blood counts (like hematocrit for PV and platelet counts for ET) and what the implications of this are for their health. Specifically, clinicians aim to keep hematocrit below 45% in PV and platelet counts below 400 x 10^9/L in ET, alongside keeping white blood cell counts in check, to reduce the risk of thrombosis and other complications. However, understanding how consistently these targets are met in routine care and whether failing to meet them early on increases the risk of adverse events like cardiovascular disease has been an open question.
Methods
The researchers conducted a retrospective analysis of anonymized electronic health records from two UK NHS Trusts, covering the period from 2008 to 2020. They focused on "high-risk" patients (defined as those aged 60 or older, or with a history of thrombotic or hemorrhagic events).
Key methodological aspects include:
- Longitudinal Modeling: They used linear mixed-effects models to track changes in peripheral blood counts (platelets, hematocrit, hemoglobin, RBC, and WBC) over a five-year period. This approach accounts for individual patient variations and the repeated measurements over time.
- Definition of Remission: Peripheral blood count remission was defined based on European LeukemiaNet (ELN) criteria, which involve specific thresholds for hematocrit (for PV), platelets, and white blood cells.
- Risk Assessment: They estimated the relative risk of cardiovascular-related events (including death, thrombosis, hemorrhage, and cardiovascular disease) for patients who achieved remission within the first three months of their diagnosis compared to those who did not.
- Statistical Adjustments: Models were adjusted for factors like age, sex, and the Charlson Comorbidity Index (CCI) to isolate the effects of remission status.
Datasets
The study utilized anonymized electronic health records (EHRs) from two UK National Health Service (NHS) Trusts:
- Chelsea & Westminster Hospital NHS Foundation Trust (CW)
- Oxford University Hospitals NHS Foundation Trust (OUH)
The data spanned from 2008 to 2020 for CW and 2012 to 2020 for OUH, providing a substantial real-world dataset of 620 ET patients and 429 PV patients.
Key Insights and Ideas
- Remission is a Moving Target: The study highlights that achieving and maintaining complete hematological remission is a significant challenge in the day-to-day management of ET and PV patients. Patients frequently move in and out of remission, suggesting that these conditions require ongoing monitoring and management.
- Platelet Target is Particularly Tricky for ET: While ET patients spent a notable amount of time in remission overall (39.2%), they were less likely to meet the specific platelet count target (48.3%) compared to the white blood cell target (79.1%). This suggests that controlling platelet levels might be a more persistent challenge in ET management.
- PV Patients Struggle with Hematocrit: For PV patients, achieving the hematocrit target (56.9%) was less common than meeting targets for platelets (77.3%) or WBC (74.6%). This points to the difficulty in consistently normalizing red blood cell production in PV.
- No Early Remission = Higher Cardiovascular Risk? Not So Fast: A crucial finding is the lack of a statistically significant association between achieving remission within the first three months and an increased risk of cardiovascular events. This is important because it suggests that while remission is a goal, failing to hit it immediately might not automatically translate to worse cardiovascular outcomes, at least within the scope of this study.
- Initial Blood Count Declines: For high-risk patients, blood counts generally decreased in the initial months of observation, likely due to treatment interventions, and then stabilized within normal reference ranges.
Key Results
- Patient Cohort: The study analyzed data from 620 ET patients and 429 PV patients.
- Time in Remission: On average, high-risk ET patients spent 39.2% of their follow-up time in peripheral blood count remission, while high-risk PV patients spent 29.1%.
- Individual Marker Remission:
- ET patients achieved remission based on platelets alone 46.4% of the time and WBC alone 76.3% of the time.
- PV patients achieved remission based on hematocrit alone 55.4% of the time, platelets alone 71.5%, and WBC alone 69.0%.
- Target Achievement:
- ET patients reached target platelet counts in 48.3% of cases, compared to 79.1% for WBC.
- PV patients reached target hematocrit levels in 56.9% of cases, compared to 77.3% for platelets and 74.6% for WBC.
- Cardiovascular Risk: No statistically significant association was found between achieving target blood counts within 3 months and an increased risk of cardiovascular events.
Limitations and Future Work
- Observational Nature: The study is observational, meaning it cannot establish causality. It couldn't directly assess how specific treatments influenced outcomes, relying on the assumption that treatments were applied according to best clinical practices at the time.
- Clinical and Molecular Similarities: The overlap in clinical and molecular features between PV and ET can make it difficult to distinguish between them, potentially leading to misrepresentation of disease pathophysiology and treatment effects.
- JAK2 Mutation Status: The limited recording of JAK2 mutation status means that some PV patients might have been misclassified or their data might be incomplete.
- EHR Data Limitations: Retrospective EHR data can make it challenging to account for all instances of lost-to-follow-up, although multilevel models were used to mitigate this.
- Future Work: The authors suggest that further longitudinal studies are needed to better understand the relationship between leukocyte count and disease outcomes, as well as to develop better prognostic models for PV and ET. They also note the need for more research into how achieving remission translates to improved patient outcomes.
Summary updated